Du är här

2016-02-05

Sanofi : Sanofi Appoints Muzammil Mansuri to Executive Committee and Executive Vice President, Strategy & Business Development

Sanofi Appoints Muzammil Mansuri to Executive Committee and Executive Vice
President, Strategy&Business Development

Paris, France - February 5, 2016
-Sanofiannounced the appointment of Muzammil "Muz" Mansuri as a new member of
the Executive Committee, effective February 22, 2016. Mr. Mansuri joins
Sanofi from Gilead Sciences and will take the position of Executive Vice
President, Strategy&Business Development.

Mr. Mansuri will be responsible for all Group strategic planning, business
development, strategic intelligence, alliance management and the Sanofi
Genzyme Bio Ventures fund.

"Muz brings a wealth of experience as a senior executive within the global
biopharmaceutical industry,"
said Olivier Brandicourt, CEO, Sanofi."Muz's deep understanding of business
development and strategy of global
biopharmaceutical organizations will allow him to contribute significantly to
the overall Group strategy and make him a valuable addition to Sanofi and the
Executive Committee."

A dual citizen of the U.S. and United Kingdom, Mr. Mansuri has more than 35
years of experience beginning in 1981 with Shell Research Limited where he
began as a research scientist. After Shell, he spent several years with
Bristol-Myers Company in various R&D roles with increasing responsibility.
From 2007 to 2010, Mr. Mansuri was Chairman and CEO at CGI Pharmaceuticals.
Mr. Mansuri's most recently was Senior Vice President, Research&Development
Strategy and Corporate Development at Gilead Sciences.

Mr. Mansuri holds a Bachelor of Science degree in Chemistry and a Ph.D in
Organic Chemistry from the University College London. He held post-doctoral
positions at the University of California, Los Angeles (UCLA) and Columbia
University.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths
in diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and Genzyme. Sanofi is listed in Paris
(EURONEXT:SAN) and in New York (NYSE:SNY).

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services, product
development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans" and similar
expressions. Although Sanofi's management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in
research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as
their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment initiatives and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the
year ended December 31, 2014. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
Contacts:

------------------------------------------------------------
| Media Relations Investor Relations |
| |
|Laurence Bollack Sébastien Martel |
|Tel. : +33 (0)1 53 77 46 46 Tel.: +33 (0)1 53 77 45 45 |
|mr@sanofi.com ir@sanofi.com |
------------------------------------------------------------
Press release (PDF)
http://hugin.info/152918/R/1983790/727153.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire

HUG#1983790

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.